血管内溶血与多药治疗预测自身免疫性溶血性贫血患者血栓形成
该研究回顾性分析1978年起意大利某三级中心287例连续自身免疫性溶血性贫血(AIHA)患者,其中174例于2020年1月至2021年12月前瞻性评估。33例(11.4%)发生血栓,70%需住院;多因素分析显示乳酸脱氢酶(LDH)、输血、利妥昔单抗和环磷酰胺治疗是血栓独立相关因素。前瞻队列中45例患者发生70次急性溶血发作,接受低分子肝素预防性抗凝者无血栓并发症,未预防者16例中发生5次血栓事件。
要点
- AIHA患者血栓发生率约11.4%,其中70%需住院。
- LDH≥1.5倍正常上限、输血、利妥昔单抗及环磷酰胺治疗与血栓独立相关。
- 前瞻队列中预防性低分子肝素抗凝者无血栓事件,未预防者16例中发生5次血栓。
核心结论
- 约11%的AIHA患者发生血栓,主要为3级,与血管内溶血、需要输血、多药治疗和感染相关,提示在这些情况下应进行初级抗凝预防。
研究设计与样本
- 回顾性研究连续纳入1978年起在意大利某三级中心诊断并随访的287例AIHA患者,其中174例于2020年1月至2021年12月前瞻性评估。
主要发现
- 33例AIHA患者(11.4%)发生血栓,其中70%需住院治疗。
- LDH≥1.5倍患者血栓累积发生率更高(HR 3.22),感染者HR 3.57,接受输血者HR 3.06,接受利妥昔单抗者HR 3.3,接受环磷酰胺者HR 2.67。
- 多因素分析显示LDH、输血、利妥昔单抗和环磷酰胺治疗是血栓独立相关因素。
- 前瞻随访174例中45例发生70次急性溶血发作,33/45例LDH≥1.5倍正常上限,17例接受低分子肝素预防性抗凝中位70天(30-300天)。
- 接受预防性抗凝者无血栓并发症,其余16例中发生5次血栓事件。
临床怎么用
- 作者认为,对于存在血管内溶血、需要输血、多药治疗和感染等情况的AIHA患者,应进行初级抗凝预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombosis may complicate autoimmune hemolytic anemia (AIHA), but its predictors are still lacking, and no clear-cut indications for anticoagulant prophylaxis are available. OBJECTIVES: To characterize frequency and severity of thromboses in AIHA patients and identify risk factors for thrombosis that may advise primary anticoagulant prophylaxis. PATIENTS/METHODS: A total of 287 consecutive AIHA patients diagnosed and followed from 1978 at a tertiary Italian center were retrospectively studied; 174 of them were prospectively evaluated from January 2020 until December 2021. AIHA relapse, thrombosis occurrence, and primary anticoagulant prophylaxis were evaluated. RESULTS: Thirty-three AIHA patients (11.4%) experienced thrombosis, 70% of whom hospitalized. The cumulative thrombosis incidence was higher in patients with lactate dehydrogenase (LDH) ≥ 1.5 (hazard ratio [HR] 3.22), in those experiencing infections (HR 3.57), receiving transfusions (HR 3.06), rituximab (HR 3.3), or cyclophosphamide (HR 2.67). By multivariable analysis, LDH, transfusions, rituximab, and cyclophosphamide treatment emerged as independent factors associated with thrombosis. Among 174 patients prospectively followed in the past 2 years, we observed 70 acute hemolytic episodes in 45 patients; 33/45 displayed LDH ≥1.5 × upper limit of normal, and 17 received anticoagulant prophylaxis with low molecular weight heparin for a median of 70 days (30-300). In those receiving prophylaxis no thrombotic complications occurred, whereas five thrombotic episodes were registered in the remaining 16 cases. CONCLUSIONS: Thrombosis was observed in about 11% of AIHA patients, mainly grade 3, and associated with intravascular hemolysis, need of transfusions, multitreatment, and infections, advising primary anticoagulant prophylaxis in these settings.
引用
- Fattizzo B, Bortolotti M, Giannotta JA, et al. Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia. J Thromb Haemost. 2022. PMID: 35555857. doi:10.1111/jth.15757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。